Health Tip: When Ulcerative Colitis Symptoms Flare
Title: Health Tip: When Ulcerative Colitis Symptoms FlareCategory: Health NewsCreated: 4/3/2013 8:35:00 AMLast Editorial Review: 4/3/2013 12:00:00 AM (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - April 3, 2013 Category: Gastroenterology Source Type: news

Well: Disparities: Surgery Results Worse on Weekends
Emergency surgeries performed on a weekend may have poorer results than the same operation performed on a weekday, a new study concludes. (Source: NYT Health)
Source: NYT Health - March 22, 2013 Category: Consumer Health News Authors: By NICHOLAS BAKALAR Tags: Crohn's Disease Colitis crohns ulcerative colitis Body Surgery and Surgeons Featured Source Type: news

Ulcerative Colitis: Weekend Surgery Adds Complication Risk Ulcerative Colitis: Weekend Surgery Adds Complication Risk
Patients with ulcerative colitis who are hospitalized on the weekends have increased risks for several postoperative complications. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Avaxia doses first patient in ulcerative colitis drug study
Clinical-stage biopharmaceutical company Avaxia Biologics has dosed the first patient in a Phase Ib clinical study of its gut-targeted anti-TNF antibody, for the treatment of ulcerative colitis. (Source: Drug Development Technology)
Source: Drug Development Technology - February 27, 2013 Category: Pharmaceuticals Source Type: news

Immune commences ulcerative colitis drug Phase II study
Israel-based Immune Pharmaceuticals has commenced a double-blind, parallel group, randomised and placebo-controlled Phase II study of bertilimumab for the treatment of moderate-to-severe ulcerative colitis. (Source: Drug Development Technology)
Source: Drug Development Technology - February 22, 2013 Category: Pharmaceuticals Source Type: news

Study Finds No Tie Between Acne Drug Accutane and Crohn'S, Colitis
New data involving 45,000 women may settle the question, experts saySource: HealthDay Related MedlinePlus Pages: Acne, Crohn's Disease, Ulcerative Colitis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 20, 2013 Category: Consumer Health News Source Type: news

Mesalazine granules once-daily dose provides similar results to twice-daily dose in patients with active, left-sided ulcerative colitis.
The objective of the MOTUS study was to show non-inferiority of once-daily mesalazine versus twice-daily dosing for the induction of remission in active ulcerative colitis. As many patients with ulcerative colitis experience left-sided disease, the aim of the new sub analysis was to assess specifically the efficacy in patients with left-sided ulcerative colitis. (Source: NeLM - News)
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news

Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product Delzicol
DUBLIN, Ireland, Feb. 5, 2013 -- Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The product will be... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 7, 2013 Category: Drugs & Pharmacology Source Type: news

BMJ review: Ulcerative colitis
Source: BMJ Area: News The BMJ has featured an evidence based review on the diagnosis and management of ulcerative colitis. The following questions are addressed:   . What is ulcerative colitis and who gets it? . What are the clinical features and associated conditions? . What is the underlying pathophysiology of ulcerative colitis? . How is ulcerative colitis diagnosed? . What is the prognosis? . What are the treatment options? . Monitoring of drug therapy in ulcerative colitis . Colorectal cancer screening in ulcerative colitis . Osteoporosis in ulcer...
Source: NeLM - News - February 6, 2013 Category: Drugs & Pharmacology Source Type: news

Uceris (Budesonide) for Treating Ulcerative Colitis
Uceris (budesonide) is glucocorticoid receptor that is indicated for the treatment of ulcerative colitis. It is developed by US-based biopharmaceutical company Santarus, in collaboration with Cosmo Technologies. (Source: Drug Development Technology)
Source: Drug Development Technology - February 6, 2013 Category: Pharmaceuticals Source Type: news

Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product
DUBLIN, Ireland, Feb. 5, 2013 -- (Healthcare Sales & Marketing Network) -- Warner Chilcott plc (WCRX) today announced that the United States Food and Drug Administration (FDA) has approved its new 400 mg mesalamine product indicated for the treatment of ul... Biopharmaceuticals, Gastroenterology, FDAWarner Chilcott, DELZICOL, mesalamine, ulcerative colitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2013 Category: Pharmaceuticals Source Type: news

Which IBD Patients Should You Refer to a Specialist?Which IBD Patients Should You Refer to a Specialist?
When is it appropriate for a primary care provider to refer patients with ulcerative colitis or Crohn disease to a gastroenterologist? Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2013 Category: Consumer Health News Tags: Gastroenterology Ask the Expert Source Type: news

Simple urine test picks up mesalamine non-adherence
A readily available urine test could identify ulcerative colitis patients who are non-adherent to their mesalamine therapy, research shows. (Source: MedWire News - Gastroenterology)
Source: MedWire News - Gastroenterology - January 24, 2013 Category: Gastroenterology Source Type: news

NICE consults on draft clinical guideline on ulcerative colitis
Source: NICE Area: News NICE is developing a clinical practice guideline on ulcerative colitis for use in the NHS in England, Wales and Northern Ireland. A draft has now been issued for consultation - this includes recommendations on the following:   . Inducing remission in people with ulcerative colitis . Treatment options for people who are considering surgery . Maintaining remission in people with ulcerative colitis . Pregnant women . Monitoring   Registered stakeholders are invited to comment on the provisional recommendations via the website (consultation dates: 21 ...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news

FDA Approves Uceris for Ulcerative ColitisFDA Approves Uceris for Ulcerative Colitis
A novel oral formulation of budesonide has received approval from the FDA for mild to moderate ulcerative colitis in adults. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 19, 2013 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

US FDA approves budesonide extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis
Source: BioSpace.com Area: News According to a report by BioSpace.com, the US Food and Drug Administration has approved UCERIST (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The approved dosing regimen for adult patients is one 9 mg tablet taken orally once daily in the morning for up to 8 weeks.   [Editor's note: Currently, budesonide capsules (Budenofalk or Entocort) are only licensed for Crohn's disease in the UK.] (Source: NeLM - News)
Source: NeLM - News - January 16, 2013 Category: Drugs & Pharmacology Source Type: news

FDA Greenlights New Oral Steroid for Colitis
(MedPage Today) -- An extended release formulation of budesonide (Uceris) for the treatment of mild-to-moderate ulcerative colitis received FDA approval Tuesday. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 15, 2013 Category: Primary Care Source Type: news

Santarus Receives FDA Approval of Uceris (budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis
SAN DIEGO--(BUSINESS WIRE)--Jan 15, 2013 - Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Uceris (budesonide) extended release tablets for the induction of remission in patients with active, mild... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 15, 2013 Category: Drugs & Pharmacology Source Type: news

Amy Brenneman part of inflammatory bowel disease awareness campaign
NEW YORK, Jan. 8 (UPI) -- Known collectively as inflammatory bowel diseases, Crohn's disease and ulcerative colitis affect about 1-in-200 people, U.S. experts say. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 8, 2013 Category: Consumer Health News Source Type: news

Crohn Disease Risk in Women Elevated by Depressive Symptoms
Researchers concluded that psychological factors might contribute to the development of this disorder but not ulcerative colitis. (Source: Consultant Live)
Source: Consultant Live - January 8, 2013 Category: Primary Care Source Type: news

Gastroenterology: Images in Clinical Medicine
Editor: V. Dimov, M.D., Assistant Professor at University of ChicagoGrey Turner's sign suggesting retroperitoneal haemorrhage. Lancet, 05/2014.Abdominal-Wall Varices in the Budd –Chiari Syndrome. NEJM, 05/2014.Biliary ileus. Lancet, 07/2012.Meconium-like Ileus in Cystic Fibrosis. NEJM, 05/2012.Achalasia. NEJM, 04/2012.Intestinal Infestation with Ancylostoma ceylanicum. NEJM, 03/2012.Kayser-Fleischer Rings in Wilson's Disease. NEJM, 03/2012.Barium Aspiration. NEJM, 03/2012.Pneumopericardium Associated with a Peptic Ulcer. NEJM, 12/2011.Abdominal calcifications secondary to cysticercosis. Lancet, 12/2011.Retinopat...
Source: Clinical Cases and Images - August 22, 2009 Category: General Medicine Tags: Gastroenterology Images Source Type: news